{"name":"Tarveda Therapeutics","slug":"tarveda-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQR193WndSb3FRdFE1aU9OYnJXYnNHRVJGY0wyX1VVNHltMTVhaHo4TUZwcWZ5THkwZ2RpczFXV1NkclQyWGY2T1dmd3hWbU9yZldETnRzMnJ1RWJzTXpxTm5uczVrTHp0UnZhRnRNVmRZY3RHRVA2RGhJejA2YkVack9yVEdPb1ZfcTdldE9xblBhUkE1TWlZWXlUTWMwZDZiTVMzUFJQUEZKSkFONE91N1ZweE5HcFpzeVo4SHFCYmFxZk53QkotMlYyd1hVRmc3R3RyWThrUUp1aDJ1VXExRmVYYm1DSVFuUTB0VEQyc1lhaHNsYVpzVXduR2Q?oc=5","date":"2026-03-24","type":"pipeline","source":"Barchart.com","summary":"Pancreatic Ductal Adenocarcinoma Pipeline Gains Significant Traction with 80+ Companies Advancing Novel Therapies | DelveInsight - Barchart.com","headline":"Pancreatic Ductal Adenocarcinoma Pipeline Gains Significant Traction with 80+ Companies Advancing Novel Therapies | Delv","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPN0hNQkNaSE5SbGtYTDRNbmY4OWV3ODJlb1ZFZW1jWW5zSklGWEtDOS1mYUJFUHdWMGxyLTN2ZDR4aFB2c0tLNnFRQ2lZTGJ6aGViRWRWT0lPRVctLVBGYzEzdFU5RTFsLWtoUW1CU2ZqUkMzQnFNVTk3bmxZZWhCQnhaMW1wdkhrSENYWC1VaUQ2a1V1NW1CYWJMbmhpUU1TenY3NjVRWW5JZUF3d25WaDZKZmhQMVN2UjF6RTluaUY4dVJGelo3N2huRlJ2b1BKRHpIVXltc3dLODNPNkt0bGN3RGg4WGdtTjU4QUdDNm9rTGhtVVd3SjB1QzdPemNKbXMzV3pSN19handVUjgzN0laVVpQNFF2N2p4dWtvcE8zd01hZmJzekZvMDA4YkVjNFlB?oc=5","date":"2024-07-09","type":"pipeline","source":"prnewswire.com","summary":"Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca - prnewswire.com","headline":"Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNdlcyRzc0UWU5ZHpXLUdsd1BFcFpKTkRuTl9xQkNoQVozR3ZTVkszMU1OdWJqb0ptR05TNHJfbFZaVFBxUlkyWkM5Sm96S1psbXNoVzlyeXRUM2FRMG53TGhVRHlna1B6c2x2UU93QzVySFA3UWJnX3pJYkRWNWRDeUI3UjVXZGdRbVRiV01RcmNrLURjVTYyWEp3dlpDUFBTaGh4aTR4dGdDbUQ0czhFNHhadnRleXRXOEdSRFBkOA?oc=5","date":"2024-06-04","type":"pipeline","source":"Healio","summary":"Durvalumab extends survival in limited-stage small-cell lung cancer - Healio","headline":"Durvalumab extends survival in limited-stage small-cell lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxOeW5uV2ZNcEp5NGhCMFd6OXZoaEpOVlRoRFl5RXhWRTFyQ2VKQlNGWDhva2pPbnVQeVl2LS03N1lHNXl5SXBEWXJLRXEzT2VmZm5pYkYtY1pLMjlwY0VjUkYzT0RJZE9uRG01bEN5RHVhSkVlWjNlVUxBSHBMTmNYdF9RaF96QnA0N3NUcUFKZ3VuM3hBeC1hQ2JveHY4d1U3NHl4SFRCLUdpTG1wa1I2Ul82SGVmNGNSM05WNHNoTkVnMHBRNG9YZ1d5bGd4NzlobnBlMVZtUUUySGF5LU5VWnRlUUppendwSERTMzIxLWRJZEg1UzR3NEJrVGs4eEhCdTVKM012Ym1lblcwLTFNYw?oc=5","date":"2022-11-10","type":"pipeline","source":"ascopost.com","summary":"Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC? - ascopost.com","headline":"Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE50c1VBcldBX3dnV0ZOSGQzRVZIcURqS2NJeGo3bTNXLU40S3Q2bnVGRXZHSjREZlQxUmR3OUF1QVdrX3VtTkhrQ1AwX194aEZpOWJodFNSU3FNU3dLV1F5elFwbUk2cy03ZGdOS2FibkhYQQ?oc=5","date":"2020-07-30","type":"pipeline","source":"Pharmaceutical Executive","summary":"Pharm Exec’s 2020 Pipeline Report - Pharmaceutical Executive","headline":"Pharm Exec’s 2020 Pipeline Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPSFhNRXVNeGQ4OGxMa29qWW8tNmJITHNQY2dQRm1iRzhiZVZ3S1h3OEwzaU8wX0psc3V0cncxODY2MFNTOXliUVpteF95X2wzMi1NQlNOYk10empSS1VUbS0yWTRfeUhKSGtaQWNtQk43OEp2Z2d5MzZJTVZpSWhqSFFaQjVNbnh1ZXlQZUdtTmlvREZCZzNrY1dQc09jR1ZHNWUtSk1JWUpFZ2Q4NF9jdlZhYk9tQzZQcEZlX0Z5aUV0WlZLOGZub3NCeEtKTVc4WHNWcUtWSEJTb1NfcVNPUjh0VVZtcm04WVlqUFduS191eGhPTWl1QzdnTHZsQzYtYkI4T3g3bGpTb2c?oc=5","date":"2020-03-19","type":"pipeline","source":"businesswire.com","summary":"Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China - businesswire.com","headline":"Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater Chi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1PZ0w5RDlVZUZ1Vmw5cHhQczVBXzJVcWR5U1ExWVlhcDdJLUhoVlNpd0ZTMWswdmY0cGJBbHpGRkNxc0psbUM3M051RkhUcUNmYzlnVFpfcjhyT0Y5YVFyWUo2dEoxc3dLSVNkb0RzYWJMR3Bhd2R0MnphQTg2NG8?oc=5","date":"2020-01-08","type":"pipeline","source":"ASCO Daily News","summary":"Pembrolizumab As a First-Line Treatment of NSCLC - ASCO Daily News","headline":"Pembrolizumab As a First-Line Treatment of NSCLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNR1FxZ0ZOLXJXTFBlYkNlcmg2d1hkMmhWUDZueUplaklZeHRrcmRPLVZIVUZKaHJhZS1JSE1oU2Q1UzlPN1A4UnlTRWYtRHNLRWpLMDBmcGt6Tk93ZzlQN0FNMDNlZndlWlRNZjBHbk5Tc3VSS3BXUjVpZUtLQnlWSFdEM3lpOTlveGhZUnRfejNPRE5QSk5Jcw?oc=5","date":"2018-09-14","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Ex-Gilead CMO Andrew Cheng to lead Akero - Fierce Biotech","headline":"Chutes & Ladders—Ex-Gilead CMO Andrew Cheng to lead Akero","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQYnVfdG1wOVQ2LUVnS0JiOFktRTdSY091dTZXVDBFb1ZfUHNnb0d1MlNORmw1bFB3Z2F6ME1oWTdqaWRVUHU0QUgwazV3Z1NUOWtPaVB3Wm13M3Q1Nk90eVhmbmJWdHdUWDhlanpQYXljdnZiS29lLTMtRTFmb2JUcW5FMzFnNXZpakhjUm13Mi13Um9q?oc=5","date":"2017-12-20","type":"pipeline","source":"BioSpace","summary":"Flagship Pioneering Secures $618M for Life Science Startup Mission - BioSpace","headline":"Flagship Pioneering Secures $618M for Life Science Startup Mission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOSTRiQWlTekdDRGMzdF9TbjlNZjdvcjh6eVV3LVN1SUl4RUNMWmFGX1NySDI2OTZfeWhoTXU4OFcxSEI2VWFlOFlkTjJKNFNNOUhyOGJCcmJxSmh2SkpuUWJCUGlDS3VpbXk5NlgySnZJSW51MkwxaXZzNWlFem43R0lyQWMtOUVoWlpSVWZkOGI3SnFxMmZEYVZQVEZFV1p1ZDhnYngwWkpISTY2dXNsUA?oc=5","date":"2017-02-03","type":"trial","source":"Fierce Biotech","summary":"Funding sets up proof-of-concept trial for Tarveda's lead Pentarin next year - Fierce Biotech","headline":"Funding sets up proof-of-concept trial for Tarveda's lead Pentarin next year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPZm1YM1NYRTJqOVV5MmhUUDA2eVVkbGdFcnBYSDg1cVR5bUItSzhRUWRON3pnMmlOcmRUei1wbHhzQnJzOXZmWUhMYU9IeVRnUGxCRTEyRXpFaGFpMWR5WklEOHRoSDV5amZGb2J0VlFLdnJtUXUxM2VBWGgzRUl1d0pVNzB1akJxVnFkcVBuTFo?oc=5","date":"2016-09-20","type":"pipeline","source":"BioPharma Dive","summary":"Madrigal sells off rights to cancer platform - BioPharma Dive","headline":"Madrigal sells off rights to cancer platform","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}